Slowing or halting the progressive dopaminergic (DA) degeneration in Parkinson's disease (PD) would delay the onset and development of motor symptoms, prolong the ef®cacy of pharmacotherapies and decrease drug-induced side-effects. We tested the potential of two orally administered novel immunophilin ligands to protect against DA degeneration in two animal models of PD. First, in an MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model, we compared an immunophilin ligand (V-10,367) documented to bind the immunophilin FKBP12 with V-13,661, which does not bind FKBP12. Both molecules could prevent the loss of striatal DA innervation in a dose-dependent fashion during 10 days of oral administration. Second, to determine whether an immunophilin ligand can protect against progressive and slow DA degeneration typical of PD, an intrastriatal 6-hydroxydopamine-infusion rat model was utilized. Oral treatment with the FKBP12-binding immunophilin ligand began on the day of lesion and continued for 21 days. At this time point, post mortem analyses revealed that the treatment had prevented the progressive loss of DA innervation within the striatum and loss of DA neurons within the substantia nigra, related to functional outcome as measured by rotational behaviour. Notably, DA ®bres extending into the area of striatal DA denervation were observed only in rats treated with the immunophilin ligand, indicating neuroprotection or sprouting of spared DA ®bres. This is the ®rst demonstration that immunophilin ligands can prevent a slow and progressive DA axonal degeneration and neuronal death in vivo. The effects of orally administered structurally related immunophilin ligands in acute and progressive models of DA degeneration are consistent with the idea that these compounds may have therapeutic value in PD.
Introduction
Parkinson's disease (PD) neuropathology is characterized by a selective degeneration of the nigrostriatal dopamine (DA) system that occurs over several years (reviewed in Calne & Eisen, 1990; Olanow & Tatton, 1999) . The available pharmacological DAsubstitution agents can alleviate PD signs during early stages of the disease, yet their ef®cacy diminishes with continued DA drug exposure, and side-effects eventually outweigh bene®ts (Oertel & Quinn, 1997; Chase, 1998) . Intracranial surgery such as pallidotomy and subthalamic nucleus electrical stimulation can relieve subsets of PD signs (Benabid et al., 1996; Lozano & Lang, 1998; Shannon et al., 1998) , and neuronal cell transplantation can replace a degenerated DA system by neuronal substitution rather than by drugs (Lindvall et al., 1989; Deacon et al., 1997; Lopez-Lozano et al., 1997; Wenning et al., 1997; Kordower et al., 1998) . However, none of these approaches appear to alter the underlying progression and course of nigrostriatal degeneration.
Impressive neuroprotection of the DA system has been observed in animal experiments utilizing growth factors (Hagg, 1998; Dunnett & Bjorklund, 1999) , antioxidants (Ebadi et al., 1996; Beal, 1999) , glutamate antagonists (Rodriguez et al., 1998) and antiapoptotic agents (Koller, 1998; Olanow et al., 1998) . The translation of these positive effects into the clinical setting has been cumbersome (or negative) due to dif®culties in routes of administration and dosing parameters (Pal®, 1998; Shoulson, 1998) . The discovery that the orally bioavailable immunosuppressive drug FK506 can enhance neurite outgrowth in cell lines and primary cultured neurons (Lyons et al., 1994; Steiner et al., 1997; Costantini et al., 1998) , protect against acute glutamate toxicity and focal ischemia (Dawson et al., 1993; Sharkey & Butcher, 1994) and stimulate nerve regrowth after sciatic nerve injury (Gold et al., 1995) raised the possibility that FK506 could be a utilized as a neuroprotective agent in PD models. FK506 binds to an intracellular protein designated FKBP12 (FK506 binding protein, 12 kDa) (Steiner et al., 1992) , and this FK506± FKBP12 complex inhibits a phosphatase called calcineurin (Liu et al., 1992) . The concentration of FK506 required for neurotrophic activity is in the range that also causes inhibition of calcineurin's activity. However, because calcineurin inhibition also suppresses immune function, chronic administration of FK506 may not be desirable for patients with neurodegenerative disease.
Interestingly, there are now compounds available that bind FKBP12 but do not inhibit calcineurin, yet produce trophic effects both in culture and in models of nerve injury and neuronal degeneration (Gold et al., 1997; Steiner et al., 1997; Costantini et al., 1998) . We recently demonstrated that one of thesè neurophilin' ligands, V-10,367, has trophic activity and induces branching of neurites from primary fetal DA neurons in culture (Costantini et al., 1998; Costantini & Isacson, 2000) .
Here we demonstrate in vivo neuroprotective effects of two orally administered neurophilin ligands, 2, 3, mouse PD model, we tested V-10,367 at oral doses from 1 to 100 mg/kg/day and V-13,661 at oral doses from 0.15 to 15 mg/kg/day. Although structurally similar, only V-10,367 potently binds FKBP12 (Ki = 0.5 nM), whereas V-13,661 does not bind FKBP12 (Ki > 25 mM). These experiments therefore allowed us to examine the importance of FKBP12 binding in mediating the protection against MPTP-induced damage. We also tested the potential for V-10,367 to protect against a progressive DA denervation using an intrastriatal 6-hydroxydopamine (6-OHDA) rat model, evaluating effects at both the morphological and functional levels. In this model, in contrast to infusion of toxin directly into substantia nigra (SN), the infusion of toxin into the striatum causes a retrograde degeneration of the DA neurons within the SN over several weeks . The results demonstrate that orally administered neurophilin ligands are protective and/or regenerative.
Materials and methods

MPTP mouse model of Parkinson's disease
Male C57/BL6 mice (9-week-old; Charles River, Wilmington, MA, USA) were injected intraperitoneally (i.p.) with 20 mg/kg MPTP (Research Biochemicals International, Natick, MA, USA) twice per day for 2 days (at 12-h intervals), then once per day for the following 3 days (total MPTP dose, 140 mg/kg) (Fig. 1A) . MPTP was made freshly each day as a 2.5-mg/mL solution in sterile saline. V-10,367, V-13,661 or vehicle (water/propylene glycol/ethanol at a ratio of 5 : 4 : 1, respectively) was administered orally by intubation once per day, 30 min prior to each MPTP injection, and for 5 more days after MPTP treatments (Fig. 1A ). Mice were randomly distributed into four treatment groups: (i) V-10,367 at 1.0, 15.0, 50.0 and 100.0 mg/kg/day, n = 8 per dose; (ii) V-13,661 at 0.15, 1.5 and 15.0 mg/kg/day, n = 10±12 per dose; (iii) MPTP alone (MPTP/veh), n = 16; (iv) vehicle alone (veh/veh), n = 15.
Mice were anaesthetized with barbiturate and perfused on day 15 and analysed histologically for striatal tyrosine hydroxylase (TH; 1 : 500; Pel-Freez, Rogers, AK, USA) ®bre density as previously described (Costantini et al., 1998) . Brie¯y, an equivalent ®eld within the dorsolateral region of the striatum from four sections per mouse (120 mm apart, thus spanning the rostral±caudal 640-mm mouse striatum) was chosen by an investigator blinded to treatment, captured in NIH Image at 20Q, and the optical density (OD) of TH + ®bre staining was obtained. In addition, one ®eld from the anterior thalamic nucleus (±1.3 mm from bregma) from each mouse was captured and an OD measurement obtained, which was subtracted from each striatal OD measurement to correct for assay background. The four ®nal OD values were averaged for each mouse. All statistical comparisons were made using analysis of variance (ANOVA), and Wilcoxon rank-sum test to de®ne signi®cant differences between groups (in JMP Version 3.1, SAS Institute, NC, USA). All experiments were approved by the McLean Hospital Institutional Animal Care and Use committee.
6-OHDA rat model of Parkinson's disease
Male Sprague Dawley rats (Charles River) (» 300 g) received bilateral intrastriatal stereotaxic injections of 3% Fluorogold (FG; Molecular Probes, Eugene, OR, USA) in saline under ketamine/ xylazine anaesthesia (60 mg/kg and 3 mg/kg, respectively) using a 2-mL Hamilton syringe ®tted with a glass micropipette at the following striatal coordinate (0.2 mL/site) (calculated from Bregma): AP +1.0; L T3.0; V ±4.5 mm; incisor bar at ±3.4 mm (3.4 mm below the ear bars). One week later (Fig. 1B) , unilateral stereotaxic injections of 6-OHDA (Sigma, St. Louis, MO, USA) or vehicle (0.2% ascorbic acid/ saline) were made (under ketamine/xylazine anaesthesia) into the right striatum using a 10-mL Hamilton syringe. A concentration of 3.0 mg/uL free base 6-OHDA dissolved in vehicle was injected into four striatal sites (2 mL/site, total dose 24 mg) at the following coordinates (calculated from bregma): site 1, AP +1.4, L ±2.6, DV ±5.0; site 2, AP +0.4, L ±3.0, DV ±5.0; site 3, AP ±0.4, L ±4.2, DV ±5.0; site 4, AP ±1.3, L ±4.5, DV ±5.0 mm. The tooth bar was set at 0 for all injections. Rate of injection was 1 mL/min, leaving the needle in place for a further 2 min before withdrawal. Rats were treated via oral intubation with V-10,367 (25 mg/kg) or vehicle (water/ propylene glycol/ethanol at a ratio of 5 : 4 : 1, respectively) beginning the day of lesion and continuing once per day for 21 days.
Rats were randomly distributed in three treatment groups: (i) 6-OHDA + V-10,367, n = 16; (ii) 6-OHDA + vehicle, n = 13 (iii) 6-OHDA + no treatment, n = 5. These last two control groups were combined for 6-OHDA + vehicle, n = 18, because no differences between 6-OHDA + vehicle and 6-OHDA + no treatment were observed.
On day 21, rats were given an injection of 3.5 mg/kg Damphetamine i.p. and placed (randomized) into automated rotometer bowls; full-body turns ipsilateral and contralateral to the lesion were monitored over a 90-min period via a computerized activity monitor system. Net rotational asymmetry scores were expressed as ipsilateral minus contralateral rotations. Rats were anaesthetized with barbiturate and perfused two days after behavioural testing (23 days postlesion) for histological analyses.
For DA neuron cell counts in the SN, three sections (200 mm apart) in which the medial region of the SN was clearly separated from the ventral tegmental area by the medial terminal nucleus of the accessory optic tract (level ±5.3 mm in the atlas of Paxinos and Watson (1986) were selected for analysis, and only TH + cells lateral to the medial terminal nucleus were counted (10Q, bright®eld). For FG + cell counts, three sections adjacent to those utilized for TH + cell To obtain information about immunophilin effects on long-term DA degeneration, a retrograde toxicity model was used. The striatum of rats was ®rst injected bilaterally with uorogold to prelabel SN DA neurons. One week later, 6-OHDA was infused unilaterally. Neuroimmunophilin treatment (V10,367) began thereafter and until death (day 21). Rats were also assessed from rotational asymmetry before killing.
counts were sampled (10Q, UV¯uorescence). Two distinct populations of FG + cells were observed (as previously reported by Sauer & Oertel, 1994) ; FG + cells were counted when they were brightly white/ yellow¯uorescent and exhibited at least one long dendrite (average cell soma diameter of 31 mm). Smaller cells (average cell soma diameter of 9.1 mm) with ®ne reticular cell processes reminiscent of phagocytic cells were excluded (Sauer & Oertel, 1994) . These cells were labelled secondary to phagocytosis of labelled cellular debris. Cell numbers (TH + and FG + ) were obtained from lesioned and unlesioned sides, and data are appropriately expressed as relative`% of unlesioned' calculated from these three sections per rat.
Quanti®cation of striatal area of lesion and TH innervation was obtained using a video capture microscope image and image analysis (NIH Image). The area of lesion was outlined and measured (in mm) in four sections per rat (200 mm apart). OD measurements of TH + innervation were taken from the lesioned and unlesioned crosssection of the entire striatum (corresponding to Paxinos and Watson +1.0, +0.5 and ±0.3 mm from Bregma, excluding the nucleus accumbens) in three sections per rat. These measurements were averaged per rat and expressed as`% unlesioned' of intact contralateral side. All comparisons of the treatment vs. the vehicle groups were made by Wilcoxon rank-sum test (nonparametric comparison). Overall, volume and area of the anatomical structures or cells analysed did not differ in any of the lesion or treatment groups and thus all sampling and comparisons were made appropriately according to morphometric methods previously published (Frim et al., 1994; Sauer et al., 1995; Lee et al., 1996; Costantini et al., 1998; Hagg, 1998; Horger et al., 1998) .
Results
Neurophilin ligands protect against MPTP-induced degeneration in the mouse
In a pilot study, utilizing the 5-day regimen of MPTP injections in mouse ( Fig. 1A ; total dose = 140 mg/kg), degeneration of the DA system was predominantly observed at the striatal level, with no signi®cant loss of TH + neurons within the SN (Costantini et al., 1998) . Therefore, this MPTP paradigm in mouse and possibly others is most appropriate for analysis of loss of TH + ®bre density in the striatum, but not actual cell loss in the SN. Quanti®cation by densitometric analysis showed that mice receiving MPTP exhibited a signi®cant decrease (» 50%) in striatal TH + ®bre density ( Fig. 2A , black bar,`MPTP/veh') when compared to unlesioned mice ( Fig. 2A , white bar,`veh/veh'). When MPTP-lesioned mice were treated orally with V-10,367 at doses ranging from 1.0 to 100 mg/kg/day ( Fig. 2A , hatched bars), a signi®cantly higher striatal TH + ®bre density was observed when compared to MPTP-lesioned mice receiving vehicle ( Fig. 2A , black bar,`MPTP/veh'). TH + ®bre density in mice treated with 15 mg/kg/day and 50 mg/kg/day doses was signi®cantly greater than in mice treated with the 1 mg/kg/day dose; the dose of 15 mg/ kg/day showed higher TH + density than vehicle-treated mice. In a preliminary experiment, V-13,661 prevented MPTP-induced loss of striatal TH ®bre density when administered orally at 15 mg/kg per day (data not shown). To determine whether lower doses can also prevent this degeneration, follow-up experiments utilized V-13,661 in this paradigm over a dose range of 0.15±15.0 mg/kg per day (Fig. 2B) . TH + ®bre density was signi®cantly greater in MPTPlesioned mice receiving 15 mg/kg/day of V-13,661 (Fig. 2B , hatched bar,`15') than in MPTP-lesioned mice receiving vehicle (Fig. 2B , black bar,`MPTP/veh'). The lower doses of V-13,661 had no effect on TH + ®bre density.
Neurophilin ligand protects against progressive 6-OHDAinduced degeneration in the rat Adult rats were injected with FG (bilaterally into striatum) to prelabel DA neurons within the SN, then injected with 6-OHDA (unilaterally into striatum) one week later (Fig. 1B) . A progressive degeneration of the DA nigrostriatal system occurs after axon terminal damage induced by this intrastriatal injection of 6-OHDA . Rats receiving unilateral injections of 6-OHDA into the striatum show a marked depletion of striatal TH + ®bres at 3 weeks postlesion (Fig. 3B ) when compared with intact side (Fig. 3A) , whilst intrinsic striatal neurons remain relatively intact (data not shown). In addition to this striatal TH loss, there was a loss of TH + neurons within the SN (Fig. 3D, 62% decrease at 23 days after lesion) when compared to the intact side (Fig. 3C) . Quanti®cation within the striatum showed that a large area of the striatum was depleted of TH + ®bres in lesioned rats treated with vehicle (Fig. 4A, white bar) . By contrast, the depleted area was signi®cantly smaller in similarly lesioned rats treated orally with V-10,367 (Fig. 4A, hatched bar) . Furthermore, quanti®cation of total striatal TH + ®bre density showed that 6-OHDA-lesioned rats treated orally with V-10,367 showed signi®cantly higher (24%) striatal TH + ®bre density when compared with lesioned rats treated with vehicle (Fig. 4B) .
Intrastriatal 6-OHDA markedly decreased the number of DA neurons in the SN ipsilateral to the lesion (Fig. 4C, white bar) . Lesioned rats treated orally with V-10,367 showed signi®cantly higher numbers of TH + neurons (Fig. 4C , hatched bar) than vehicletreated rats. Intrastriatal 6-OHDA also induced a loss of a subset of FG + cells within the SN. Rats treated with V-10,367 showed more FG + cells (27.7% T 4.48 SEM of unlesioned FG + cells) than rats treated with vehicle (22.52% T 2.82 of unlesioned FG + cells) although this difference was not statistically signi®cant (P = 0.493). FG prior to lesion was injected at one site within the striatum, whereas 6-OHDA was subsequently administered to four sites within the striatum. Therefore, FG-labelled cells probably represented only a subset of the neurons exposed to 6-OHDA.
Interestingly, detailed microscopic analysis of the striatum in 6-OHDA-lesioned rats treated with neurophilin ligand clearly demonstrated the presence of TH + ®bres extending from the border of the denervated area of striatum towards the centre of this area of total TH + loss (Fig. 5A ). Such ®bre patterns were never observed in striatum of vehicle-treated rats (Fig. 5B) .
Rats receiving direct 6-OHDA infusions into the neostriatum (unilateral) have highly variable rotations (ipsilateral to the lesion) when exposed to DA-releasing drugs such as amphetamine (Dunnett et al., 1983; Dunnett et al., 1987) . This limits the use of this model. However, in the present study, we observed amphetamine-induced rotation 21 days after the progressive 6-OHDA lesion (Fig. 4D) , and many rats treated orally with V-10,367 displayed a tendency for less motor asymmetry than did vehicle-treated lesioned rats, although these differences did not reach statistical signi®cance as a group (P = 0.208).
Discussion
Experimental strategies to slow or halt neuronal cell death and stimulate axonal regeneration in the CNS include several neurotrophic factors, antioxidants and antiapoptotic agents. Protective effects in animal models of PD have been obtained with various molecules including GDNF (reviewed in Bjorklund et al., 1997; Rosenblad et al., 1999) , neurturin (Horger et al., 1998; Tseng et al., 1998; Akerud et al., 1999; Rosenblad et al., 1999) 1993). However, clinical application has been limited because of dif®culties in delivery and side-effects. These peptides do not readily diffuse across the blood±brain barrier or ventricular lining and have limited or unstable bioavailability and some toxicity (Kordower et al., 1999) . The present study shows signi®cant protection of the nigrostriatal system with orally administered nonpeptidergic factors in animal models of PD.
Orally administered neurophilin ligands are protective in rodent models of PD
We previously demonstrated (at higher doses than those presented here) that the neurophilin ligand V-10,367 (which binds and inhibits the immunophilin FKBP12) can induce branching of neurites from primary DA neurons in culture (Costantini and Isacson, 2000) , and completely protect against MPTP-induced loss of striatal DA innervation after oral administration (Costantini et al., 1998) . Other studies have observed similar effects in an MPTP mouse model after subcutaneous delivery of an FKBP12-binding compound (Steiner et al., 1997) . Here, we show that the effects of neurophilin ligands V-10,367 and V-13,661 correlate with oral dose and can confer complete protection against MPTP-induced toxicity. These effects do not appear to require interaction with FKBP12, because V-13,661 does not bind to FKBP12. Although one dose of V-10,367 (15 mg/kg/ day) produced supranormal levels of TH + staining ( Fig. 2A) , the difference in TH density is modest and may re¯ect TH protein levels (induction) rather than axonal density increases (Costantini et al., 1998) . Whether such TH induction results in increased DA release must be experimentally determined. Most probably, the dual controls of DA release and reuptake will be more important for DA concentration at the synapses than an increased activity of L-dopasynthesizing enzymes (such as TH). This positive effect is relevant in a clinical sense only by reference to trophic support of as yet undamaged remaining striatal innervation in PD patients, because they present with signs after » 80% loss of striatal DA.
In a second part of this investigation, we utilized an intrastriatal 6-OHDA lesion model which is more analogous to the progressive DA degeneration seen in PD. In this model, atrophy of striatal DA terminals begins within one week after lesion and is followed by rapid, yet partial, cell death of DA cells within the SN . There is long-term atrophy of SN DA neurons and TH downregulation 1±4 weeks after lesion. The incomplete loss of DA neurons and partial remaining striatal TH + ®bres resemble the early Rats treated with V-10,367 showed a signi®cantly smaller area of 6-OHDAinduced loss of striatal TH + ®bres when compared with vehicle-treated rats (*P < 0.05). (B) Quanti®cation of striatal TH + ®bre density after intrastriatal injection of 6-OHDA revealed signi®cant decreases in ®bre density in rats treated with vehicle, whilst lesioned rats treated with V-10,367 maintained signi®cantly higher (57% of unlesioned) TH + ®bre density (*P < 0.05). (C) Quanti®cation of TH + cells within the SN revealed a signi®cantly higher number of TH + cells in lesioned rats treated with V-10,367 when compared with lesioned rats treated with vehicle (*P < 0.05). (D) When tested for amphetamine-induced rotation 21 days after progressive 6-OHDA lesion, there was a trend towards a decrease in rotation in V-10,367-treated rats (P = 0.208).
FIG. 5.
Morphological analyses of striatal 6-OHDA lesion. Upon microscopic analyses of the striatum in 6-OHDA-lesioned rats, TH + ®bres were observed within the core of the lesion only in (A) neurophilin ligandtreated rats when compared with (B) the core of vehicle-treated rats 23 days after lesion. stages of PD, leaving part of the nigrostriatal system intact as a potential substrate for sprouting and functional recovery after administration of growth-promoting factors . Notably, within the striatum of neurophilin ligand-treated rats, TH + ®bre innervation was maintained to almost 60% of unlesioned levels, suggesting that the neurophilin ligand protected DA ®bres, induced regeneration or sprouting from spared DA ®bres, or prevented the lesion-induced decreases in TH levels (prevention of the downregulation of TH would still serve to enhance the biochemical functionality of the injured nigrostriatal system).
In addition, we found TH + ®bres extending into the area of TH + loss within the striatum (Fig. 5) , suggesting that sprouting of spared ®bres in the area of lesion may have occurred. Alternatively, but less likely, would be a protection of a subpopulation of striatal ®bres around the core of the lesion. An analogous sprouting effect of TH + axons has been observed within the globus pallidus when GDNF was administered (injected into striatum or ventricle) every third day for 4 weeks beginning the day after progressive 6-OHDA lesion, though no sprouting or regrowth of DA axon terminal were seen within the striatum (Rosenblad et al., 1999) . In the SN, the protection of TH + neurons in neurophilin-treated rats after 6-OHDA may re¯ect a protection of the acute-phase cell death of SN neurons after lesion. Previously, subcutaneous delivery of a FKBP12-binding compound (GPI-1046) was shown to increase striatal TH + ®bre density to 36±43% of unlesioned levels when administered after an acute lesion of the rat nigrostriatal system (intranigral 6-OHDA), and to decrease amphetamine-induced rotations; however, analysis of surviving SN DA cell number was not presented (Steiner et al., 1997) . In a separate study, utilizing the same FKBP12-binding compound in the acute intranigral 6-OHDA model, Harper and colleagues observed no sparing effect of GPI-1046 on striatal TH + ®bres or SN DA neurons after subcutaneous delivery; no reduction in amphetamine-induced rotations was observed in animals treated with this compound, though the duration of circling behaviour was reduced (Harper et al., 1999) . Delayed treatment with GPI-1046, starting 14 days after lesion, showed no behavioural or morphological effects. Notably, this study reported that GPI-1046 is rapidly cleaved after systemic administration, generating an apparently biologically inactive free acid. Further studies will be required to resolve these observations. How do orally administered neurophilin ligands compare with intracranially injected peptidergic factors in rodent models of PD?
Protective and regenerative effects similar in magnitude to the present ®ndings with neurophilin ligands in the progressive 6-OHDA lesion model have been obtained with trophic peptide factors, though their optimal route of administration has yet to be determined. For example, repeated intranigral injections of GDNF beginning 5 or 7 days after lesion (when the terminal degeneration is ongoing but prior to DA cell death) produced protection of TH + neurons, though less complete protection of FG + cells (Sauer et al., 1995; Winkler et al., 1996) . In contrast to our observations with V-10,367, Winkler et al. (1996) did not observe protection of striatal DA innervation or sprouting into the lesioned area, and no effects on amphetamineinduced rotation or forelimb akinesia were detected (Winkler et al., 1996) . Intranigral injection of GDNF one day prior to lesion spared a proportion of SN cells, yet only half of the spared neurons were TH + , suggesting that GDNF does not affect TH levels (Kearns & Gash, 1995) . Similarly, repeated neurturin (a peptidergic factor related to GDNF) or GDNF injected into SN beginning 3 days after lesion spared FG + cells but not TH + cells (Horger et al., 1998) , consistent with GDNF effects on cell survival but not TH expression. This SN population may contain protected neurons (FG + but TH ± ) that are unable to produce suf®cient levels of TH to have functional capacity. In contrast, the present data demonstrate signi®cant protection of TH + cells after treatment with V-10,367, consistent with a trend in the same direction for FG + neurons. Studies of intranigral infusion of GDNF after medial forebrain-bundle lesion of the nigrostriatal pathway, either prior to lesion (Lu & Hagg, 1997) or 2 weeks after lesion (Bowenkamp et al., 1995) , demonstrated sparing of TH + cells but no effect on striatal innervation or lesion-induced decreases in TH levels.
Improved effects following GDNF administration were obtained in studies utilizing intrastriatal administration after 6-OHDA lesion, perhaps because GDNF injected into striatum may more effectively accumulate in the SN through retrograde transport (Tomac et al., 1995) . Intrastriatal GDNF injected at the time of lesion protected TH + cells, partially spared striatal TH + innervation (5±15% of unlesioned) in the area around the injection site, and produced a 50% reduction in amphetamine-induced rotation (Shults et al., 1996) . Repeated injections of GDNF into striatum or ventricle (ICV) beginning one day after lesion protected TH + (and FG + ) neurons, but had no effect on striatal DA innervation or amphetamine-induced rotation (Rosenblad et al., 1999) . However, intrastriatal injection of GDNF beginning 4 weeks after 6-OHDA restored striatal DA innervation to 70±95% of unlesioned levels, increased numbers of surviving TH + cells by 20% and normalized forelimb stepping de®cits . Neurturin partially protected TH + neurons only after intrastriatal administration, but showed no effect after ICV injection (Rosenblad et al., 1999) . This illustrates the problematic diffusion kinetics of peptidergic factors after intracranial administration, resulting in limited diffusion and hence incomplete protection of damaged areas. The lack of protection observed with ICV neurturin is presumably due to its poor solubility and diffusion kinetics (Rosenblad et al., 1999) . Systemic-delivery methods for neuropeptides have been developed and tested with success in animal PD models, such as conjugation of the trophic factor to a transferrin receptor antibody (Backman et al., 1996) . In contrast, as described here, neurophilin ligands exert growth-promoting effects on both spared and damaged axons as well as TH + neurons in the lesioned adult nigrostriatal DA system after oral administration.
Potential relationship between morphological and behavioural effects
In our current experiments, the trend towards normalization of rotational behaviour in the 6-OHDA-lesioned rats receiving V-10,367 suggests that the observed morphological effects at the nigral and striatal levels were functionally relevant. Although protection was not complete, the maintenance of almost 60% of striatal DA innervation and almost 50% of DA neurons could potentially overcome the threshold for Parkinsonian symptoms (Dunnett & Bjorklund, 1999) . Depending on the lesion and behavioural paradigm, studies have shown a close correlation between degree of striatal DA levels (or DA uptake sites) and drug induced amphetamine rotation (Przedborski et al., 1995; Lee et al., 1996) . However, in protective/ regenerative paradigms (GDNF) in the model utilized in our study, improvement in forelimb use can occur in the absence of signi®cant effects on amphetamine-induced rotation (Winkler et al., 1996; Rosenblad et al., 1998; Rosenblad et al., 1999) . What could explain these apparent differences in recovery in the striatal DA toxicity model? The intrastriatal delivery of 6-OHDA could cause additional striatal neuronal cell dysfunction, even after a mild lesion, though no apparent damage was observed in the present study. In addition, the time course of trophic factor treatment may play a role in the effects observed; analysis in the present study was performed one day after the last oral administration of neurophilin ligand, at 3 weeks after lesion. It is possible that signi®cant functional recovery may develop over a longer time period. Future studies are needed to evaluate these possibilities.
In summary, we have demonstrated protection by neurophilin ligands of the DA system in one acute and one progressive degeneration model of PD. The neurotrophic effects of neurophilin ligands after oral administration were similar to those obtained with intracerebrally delivered neurotrophic factors in such animal models.
